Mylan (MYL) Given a $31.00 Price Target at Cowen

Cowen set a $31.00 target price on Mylan (NASDAQ:MYL) in a report released on Tuesday. The brokerage currently has a hold rating on the stock.

Other research analysts also recently issued reports about the stock. Mizuho reaffirmed a buy rating and set a $54.00 price objective on shares of Mylan in a research report on Wednesday, August 8th. Citigroup lowered their price objective on shares of Mylan from $50.00 to $48.00 and set a buy rating on the stock in a research report on Thursday, August 9th. Bank of America raised shares of Mylan from a neutral rating to a buy rating and decreased their target price for the stock from $44.00 to $42.00 in a research report on Tuesday. Morgan Stanley downgraded shares of Mylan from an overweight rating to an equal weight rating and decreased their target price for the stock from $46.00 to $36.00 in a research report on Tuesday, October 9th. Finally, Wells Fargo & Co reissued a hold rating on shares of Mylan in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the company. The company has an average rating of Buy and an average price target of $46.87.

MYL traded down $0.20 on Tuesday, reaching $36.95. 4,300,237 shares of the company traded hands, compared to its average volume of 6,462,479. Mylan has a 52-week low of $30.33 and a 52-week high of $47.82. The company has a market capitalization of $18.84 billion, a PE ratio of 8.10, a PEG ratio of 1.20 and a beta of 1.53. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.77 and a current ratio of 1.26.

Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Monday, November 5th. The company reported $1.25 EPS for the quarter, beating the Zacks’ consensus estimate of $1.19 by $0.06. Mylan had a net margin of 4.71% and a return on equity of 19.39%. The firm had revenue of $2.86 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same period in the previous year, the firm posted $1.10 earnings per share. The firm’s revenue was down 4.2% on a year-over-year basis. On average, equities analysts forecast that Mylan will post 4.68 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Pzena Investment Management LLC lifted its stake in shares of Mylan by 2.6% in the third quarter. Pzena Investment Management LLC now owns 21,657,877 shares of the company’s stock worth $792,678,000 after buying an additional 542,725 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Mylan by 8.7% in the third quarter. Bank of New York Mellon Corp now owns 10,226,277 shares of the company’s stock worth $374,280,000 after buying an additional 818,059 shares during the last quarter. FMR LLC lifted its stake in shares of Mylan by 1.9% in the second quarter. FMR LLC now owns 9,171,840 shares of the company’s stock worth $331,470,000 after buying an additional 168,347 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Mylan by 2.7% in the second quarter. Janus Henderson Group PLC now owns 5,389,463 shares of the company’s stock worth $194,776,000 after buying an additional 144,075 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Mylan by 14.4% in the second quarter. Dimensional Fund Advisors LP now owns 5,132,430 shares of the company’s stock worth $185,499,000 after buying an additional 644,643 shares during the last quarter. 82.99% of the stock is owned by institutional investors.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

Featured Story: What is insider trading?

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply